PitchSend

argenx SE Investor Day Presentation Deck

Biology Rationale is at the Core of our Indication Selection Preclinical Evidence Passive transfer model of IMNM autoantibodies from patient serum induce muscle weakness and loss of grip strength in mice argenx Y Clinical Evidence No approved targeted therapies for myositis but common immune therapies* show correlation of autoantibodies to disease progression ● ● ● Correlation of identity of autoantibodies to muscle damage across myositis subtypes Direct link between titer of autoantibody and disease activity Rituximab and IVlg evidence demonstrate autoantibodies are foundational drivers of disease *Plasmapheresis and immunoadsorption (commonly used as correlates for efgartigimod) are not used in the treatment of myositis 30

View entire presentation